Opis działalności
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Osamu Okuda |
| Zarząd |
| Toshiaki Itagaki |
| Rada nadzorcza |
| Dr. Osamu Okuda, Dr. Hisafumi Yamada, Toshiaki Itagaki, Dr. Mariko Y Momoi, Dr. Fumio Tateishi, Hideo Teramoto, Dr. Christoph Franz, Dr. James H. Sabry, Teresa A. Graham |
Dane firmy
| Nazwa: |
Chugai Pharmaceutical Co., Ltd. |
| Adres: |
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku,Tokyo 103-8324 |
| Telefon: |
+81-(0)3-3281-6611 |
| Fax: |
+81-(0)3-3281-6607 |
| E-mail: |
-
|
| Internet: |
https://www.chugai-pharm.co.jp/english/index.html |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
- |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
- |
| Telefon: |
+81-(0)3-3273-0554 |
| Fax: |
+81-(0)3-3281-6607 |
| E-mail: |
-
|
